Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
(4) - EconoTimes)
CAMBRIDGE, Mass., April 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on April 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to forty individuals hired by Sarepta in April 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 170,959 shares of Sarepta's common stock. The options have an exercise price of $76.36 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2018. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
